IL1B and congenital rubella syndrome: The other potential targets in the treatment of CRS could be IL-1 and IL-17, and the future clinical trials are needed to show the effectiveness and benefit of developing the drugs targeting their receptors and molecules involved in their signaling pathways (Cao, 2020).